Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
复制标题
DOI：
10.1002/cncr.29812
复制
发表时间：
2016-03-01
期刊：
影响因子：
6.2
通讯作者：
Ramalingam, Suresh S.
中科院分区：
文献类型：
--
作者：
Steuer, Conor E.;Behera, Madhusmita;Berry, Lynne;Kim, Sungjin;Rossi, Michael;Sica, Gabriel;Owonikoko, Taofeek K.;Johnson, Bruce E.;Kris, Mark G.;Bunn, Paul A.;Khuri, Fadlo R.;Garon, Edward B.;Ramalingam, Suresh S.
致癌驱动因素的发现开启了肺癌的新纪元，但这些突变在不同种族/少数民族中的作用尚未得到充分研究。对肺癌突变联合会1(LCMC1)数据库进行了调查，以评估在少数民族患者群体中肺腺癌致癌驱动因素的频率和影响。来自美国14个地点的转移性肺腺癌患者参加了LCMC1。肿瘤标本收集自2009年至2012年，对10个致癌驱动因素(KRAS、EGFR、ALK重排、ERBB2(以前的HER2)、BRAF、PIK3CA、MET扩增、NRAS、MEK1、AKT1)进行多重基因分型。患者被分类为高加索人、亚洲人、非裔美国人(AA)和拉丁裔。确定了驱动程序突变频率、治疗方法和诊断后的存活率。纳入1007例患者。高加索人占多数，N=838，AA N=60，亚裔N=48，拉丁裔N=28。亚裔患者致癌司机的比例最高，为39人(81%)，其次是拉丁裔19人(68%)，高加索人511人(61%)和再生障碍性贫血32人(53%)。在再障患者中，EGFR突变频率为22%，KRAS突变频率为17%，ALK突变频率为4%。亚洲患者最有可能接受靶向治疗(51%)，而再生障碍性贫血患者的这一比例为27%。两组患者的总体存活率没有显著差异。肺腺癌致癌驱动因素的患病率和随后的治疗在不同种族之间存在差异。AA患者中司机的频率最低；然而，超过一半的AA患者有司机，并且那些接受靶向治疗的患者的结果与其他种族相似。
The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities is understudied. The Lung Cancer Mutation Consortium 1 (LCMC1) database was investigated to evaluate the frequency and impact of oncogenic drivers in lung adenocarcinomas in the racial/ethnic minority patient population. Patients with metastatic lung adenocarcinomas from 14 United States sites enrolled in the LCMC1. Tumor samples were collected from 2009 through 2012, with multiplex genotyping performed on 10 oncogenic drivers (KRAS, EGFR, ALK rearrangements, ERBB2 (formerly HER2), BRAF, PIK3CA, MET amplification, NRAS, MEK1, AKT1). Patients were classified as Caucasian, Asian, African-American (AA), and Latino. Driver mutation frequency, treatments, and survival from diagnosis were determined. 1007 patients were included. Caucasians represented the majority with N=838, AA N=60, Asians N=48, and Latinos N=28. Asian patients had the highest rate of oncogenic drivers with 39 (81%), followed by Latinos 19 (68%), Caucasians 511 (61%) and AA 32 (53%). In AA, EGFR mutation frequency was 22%, KRAS 17%, and ALK 4%. Asian patients were most likely to receive targeted therapies (51%), compared to 27% in AA. There were no significant differences in overall survival. Differences are observed in the prevalence of oncogenic drivers in lung adenocarcinomas and consequent treatments among racial groups. The lowest frequency of drivers was seen in AA patients; however, over half of AA patients had a driver and those treated with targeted therapy outcomes similar to those of other races.
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
45.3
作者：
Scagliotti, Giorgio Vittorio;Parikh, Purvish;Gandara, David
通讯作者：
Gandara, David
影响因子：
20.4
作者：
Arrieta, Oscar;Cardona, Andres F.;Cuello, Mauricio
通讯作者：
Cuello, Mauricio
影响因子：
20.4
作者：
Reinersman, J. Matthew;Johnson, Melissa L.;Kris, Mark G.
通讯作者：
Kris, Mark G.
影响因子：
158.5
作者：
Bach, PB;Cramer, LD;Begg, CB
通讯作者：
Begg, CB